Organon & Co | Des Atouts



Assets Changement Date
Adcock Ingram Holdings ZAR 8.35B 25.86M 2024-06
Bristol-Myers Squibb USD 92.43B 176M 2025-03
Celltrion KRW 20.31T 180.03B 2024-09
Cspc Pharmaceutical CNY 44.39B 3.51B 2024-12
Dianthus Therapeutics USD 374.01M 19.76M 2024-12
Ecofibre AUD 71.25M 1.95M 2024-06
Gilead Sciences USD 56.43B 2.56B 2025-03
Glaxosmithkline GBP 59.46B 1.41B 2024-12
Kangmei Pharma CNY 14.19B 63.4M 2024-09
Knight Therapeutics CAD 962.29M 16.93M 2024-09
Laboratorios Farma EUR 832.02M 25.3M 2024-12
Malin Corporation EUR 128.4M 11.8M 2024-06
Medical Developments International AUD 59.16M 31.9M 2024-06
Merck USD 117.11B 426M 2024-12
Neuren Pharmaceuticals AUD 409.71M 181.55M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Organigram Holdings CAD 479.21M 71.35M 2024-12
Organon & Co USD 13.1B 349M 2024-12
Pharma Mar EUR 333.5M 16.15M 2025-03
Qiagen NV USD 5.69B 580.57M 2024-12
Sartorius EUR 10.11B 9.3M 2025-03
Sino Biopharmaceutical CNY 65.41B 1.3B 2024-12
Tilray USD 4.19B 70.11M 2024-11



Organon & Co Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.